{content}

Study list

Rösner

Germany
|
2023-2025
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention

ALL-VASCOR

Poland
|
2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Allopurinol

CoviVa

Germany
|
2023-2027
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Neurostimulation

MonVIP

France
|
2023
  • Adults (18-64 years)
  • Fragile population
  • People at high risk of STIs
  • Immunocompromised host
  • PrEP users
  • People living with HIV
  • Hospital
  • Outpatient clinic
  • Infectious diseases unit
  • Monkeypox virus
  • Mpox

Stengel

Germany
|
2023
  • Adults (18-64 years)
  • General population
  • Healthcare workers
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

Goedecke

Germany
|
2023-2025
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Immunoadsorption

Moderna mRNA-1769-P101

United Kingdom
|
2023-2025
  • Adults (18-64 years)
  • General population
  • Monkeypox virus
  • Mpox
  • Pharmacological intervention
  • Vaccination
  • mRNA-1769

Chitgupi

Colombia Finland Ghana Honduras India Spain Thailand United States
|
2023-2024
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Bahr

Germany
|
2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

PCS TeR

Germany
|
2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

STD-MAR/Mpox

Spain
|
2023
  • Adults (18-64 years)
  • People at high risk of STIs
  • PrEP users
  • People living with HIV
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Mpox
  • Blood sample
  • Pharmacological intervention
  • Vaccination
  • JYNNEOS

Bellmann-Strobl

Germany
|
2023-2025
  • Adults (18-64 years)
  • General population
  • Outpatient clinic
  • Community
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • vasodilator
  • Vericiguat

BLOC

Austria Finland Germany Spain Switzerland
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • BC 007

Dalton

United Kingdom
|
2023-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Probiotic

PYCNOVID

Switzerland
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Pycnogenol

Jacobi

Germany
|
2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

Plaza

Spain
|
2023-2025
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

STWandRVD

Italy
|
2023-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Hydrotherapy

EJerSA-COVID-19

Spain
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation
  • Physical activity

PanoramicNOR

Norway
|
2023-2026
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir

IAMPOCO

Germany
|
2023-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Immunoadsorption

Fellerhoff

Germany
|
2023
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation
  • Fimo Health App

Gentile

Italy
|
2023-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab

PROLIFIC

Sweden
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir